EcoDrugPlus

Dopamine Receptor D1

Ensembl ID : ENSMMDG00005022768
Gene Symbol: DRD1
1 Cross references
189 Possible Orthologues:

Dopamine Receptor D2

Ensembl ID : ENSMMDG00005010478
Gene Symbol: DRD2
3 Cross references
208 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSMMDG00005004131
Gene Symbol: DRD3
1 Cross references
203 Possible Orthologues:

Dopamine Receptor D5

Ensembl ID : ENSMMDG00005004410
Gene Symbol: DRD5
3 Cross references
147 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSMMDG00005004987
Gene Symbol: LOC115358158
3 Cross references
212 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2-Like

Ensembl ID : ENSMMDG00005002024
Gene Symbol: LOC115375073
3 Cross references
200 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSMMDG00005007612
Gene Symbol: ENPP2
1 Cross references
226 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSMMDG00005024141
Gene Symbol: EGLN1
3 Cross references
200 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSMMDG00005007606
Gene Symbol: EGLN3
3 Cross references
201 Possible Orthologues:

Endothelial Pas Domain Protein 1b

Ensembl ID : ENSMMDG00005009085
Gene Symbol: EPAS1B
1 Cross references
210 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSMMDG00005011284
Gene Symbol: ECE1
3 Cross references
230 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSMMDG00005007979
Gene Symbol: EDNRA
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).